The IKBKB Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A2780 human ovarian adenocarcinoma cell line. This product features targeted disruption of the IKBKB gene, encoding I??B kinase beta (IKK??), a catalytic subunit of the IKK complex essential for canonical NF-??B signaling. The polyclonal pool provides a heterogeneous loss-of-function model, avoiding clonal artifacts and enabling robust functional genomics studies in an epithelial ovarian cancer context.
The A2780 cell line, established from an untreated patient, is a cisplatin-sensitive epithelial model widely used in ovarian cancer research. It exhibits adherent growth and is valued for studying drug resistance, apoptosis, and tumor-stroma interactions. Its well-characterized signaling networks make it an ideal host for IKBKB knockout to dissect gene contributions to ovarian carcinoma pathogenesis.
IKBKB encodes IKK??, the catalytic subunit that forms the IKK complex with IKK?? and regulatory NEMO/IKK??. Activated by upstream signals such as TNF??, IL-1??, or LPS via TAK1 and adaptors TRAF2/TRAF6/RIPK1, IKK?? phosphorylates I??B?? at Ser32/36, triggering its ubiquitination and degradation. Freed NF-??B dimers (p65/p50) then transcribe targets like IL6, IL8, BCL2, and BIRC5. Negative regulators A20 and CYLD deubiquitinate intermediates, controlling pathway output. Thus, IKK?? integrates inflammatory and survival signals.
In ovarian cancer, constitutive IKK??/NF-??B activity promotes proliferation, chemoresistance, and metastasis. Using A2780 cells, disruption of IKBKB enables investigation of pathway resetting: altered I??B?? and p65 phosphorylation, reduced target gene expression, and increased sensitivity to platinum drugs like cisplatin. The polyclonal model also permits study of compensatory mechanisms, such as non-canonical NF-??B activation or kinase crosstalk, in a relevant tumor background.
These knockout cells support western blotting for IKK?? and phospho-I??B??, RT-qPCR of NF-??B targets, luciferase reporter assays, and ChIP for p65 binding. Functional assays include flow cytometry for cisplatin-induced apoptosis (Annexin V/PI), viability tests (MTT, CellTiter-Glo), and transwell migration/invasion assays. Co-immunoprecipitation can examine IKK complex remnants. This polyclonal IKBKB knockout pool is a versatile tool for dissecting NF-??B biology in ovarian cancer. For more information, contact Ascent Research.
